Extremities

Canada Carbon Receives Full Assay Results on its Asbury Property, Including 12.25%Cg over 22.50 Metres

Retrieved on: 
Monday, March 18, 2024
Property, SGS, News, Nature, Extremities, Uranium mining

These results have also been shared with SGS Canada in order to produce a geological model that will help with the interpretation of the results.

Key Points: 
  • These results have also been shared with SGS Canada in order to produce a geological model that will help with the interpretation of the results.
  • The current program was located approximately 4 km from the Asbury mine and the conductor anomalies clearly connect the two extremities of the Asbury claim area.
  • Graphitic carbon was determined by calculating the difference from the carbon assay (after ashing) by tube furnace/coulometer minus the carbonate carbon (after ashing) by coulometry.
  • Three graphite standards were used during the drilling program, one low-grade graphitic carbon (0.13% graphitic carbon: GGC-07); three high-grade graphitic carbon (2.41% graphitic carbon: GGC-09; 2.03% graphitic carbon: OREAS 722 and 5.87% graphitic carbon: OREAS 723) standards.

Canada Carbon Receives Full Assay Results on its Asbury Property, Including 12.25%Cg over 22.50 Metres

Retrieved on: 
Monday, March 18, 2024
Property, SGS, News, Nature, Extremities, Uranium mining

These results have also been shared with SGS Canada in order to produce a geological model that will help with the interpretation of the results.

Key Points: 
  • These results have also been shared with SGS Canada in order to produce a geological model that will help with the interpretation of the results.
  • The current program was located approximately 4 km from the Asbury mine and the conductor anomalies clearly connect the two extremities of the Asbury claim area.
  • Graphitic carbon was determined by calculating the difference from the carbon assay (after ashing) by tube furnace/coulometer minus the carbonate carbon (after ashing) by coulometry.
  • Three graphite standards were used during the drilling program, one low-grade graphitic carbon (0.13% graphitic carbon: GGC-07); three high-grade graphitic carbon (2.41% graphitic carbon: GGC-09; 2.03% graphitic carbon: OREAS 722 and 5.87% graphitic carbon: OREAS 723) standards.

Henry Schein Completes Acquisition of Majority Interest of TriMed, Inc.

Retrieved on: 
Thursday, April 4, 2024
Medical Devices, Health, Dental, Physical Therapy, Managed Care, Partnership, Patient, Foot, Sale, Acquisition, Ankle, MD, ASC, Extremities, Internationalized domain name, Wrist, Outpatient surgery

Henry Schein announced the agreement to acquire a majority interest of TriMed on December 20, 2023.

Key Points: 
  • Henry Schein announced the agreement to acquire a majority interest of TriMed on December 20, 2023.
  • The addition of TriMed will strengthen Henry Schein’s deep and longstanding relationship with existing Integrated Delivery Networks (IDNs) and Ambulatory Surgery Center (ASC) customers by providing a wider range of surgical solutions.
  • This reflects the Company’s strategy to expand the sale of Henry Schein-owned brands to new and existing customers.
  • Henry Schein expects the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter.

THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) IS NOW ACCEPTING APPLICATIONS FOR TWO AACS CERTIFIED COSMETIC SURGERY FELLOWSHIP TRAINING PROGRAMS

Retrieved on: 
Monday, April 1, 2024
AACS, Interest, DDS, Patient, Breast, American Academy, Surgeon, Plastic surgery, Rhinoplasty, Skin, Blepharoplasty, Extremities, FACS, DMD, Physician, Dentistry

CHICAGO, April 1, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS), the world's largest multi-specialty organization for physicians dedicated to cosmetic surgery and aesthetic medicine, is accepting applications for July 2025 cohort positions for two types of AACS Certified Fellowship Training Programs. Applications are due by June 1, 2024.

Key Points: 
  • Applications for AACS Certified Cosmetic Surgery Fellowships in General Cosmetic Surgery and Facial Cosmetic Surgery, which offer comprehensive, world-class training, will be accepted until June 1, 2024 for July 2025 cohort positions
    CHICAGO, April 1, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS) , the world's largest multi-specialty organization for physicians dedicated to cosmetic surgery and aesthetic medicine, is accepting applications for July 2025 cohort positions for two types of AACS Certified Fellowship Training Programs.
  • AACS Certified Cosmetic Surgery Fellowships are the only cosmetic surgery training programs that fully prepare physicians for a career in cosmetic surgery, offering extraordinary opportunities for intensive, hands-on training in a vast array of cosmetic surgery procedures alongside some of the world's leading cosmetic surgeons.
  • Offered in General Cosmetic Surgery and Facial Cosmetic Surgery, these Certified Fellowships are post‐residency programs involving advanced education and comprehensive training in the art of general cosmetic surgery and facial cosmetic surgery.
  • Ryan Diepenbrock, DDS, FAACS, Chair of the Facial Cosmetic Surgery Fellowship Committee, adds, "AACS Fellowships provide the training needed to successfully practice as a cosmetic surgeon.

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Retrieved on: 
Monday, February 26, 2024
FDA, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Tardive dyskinesia, Chorea, VMAT2, Metabolism, EVP, Deuterium, Annual report, TEVA, Marketing, Teva, Partnership, HD, Quality of life, Food, Schizophrenia, Neurological disorder, DSM-IV codes, Globalization, Neuro, Prevalence, Happy Mood, Face, Anesthesia, Central nervous system disease, Pivot, Tongue, CNS, Psychiatry, Patient, Pain, Disease, Extremities, Research, Pharmaceutical industry

The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.

Key Points: 
  • The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
  • “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee, General Manager of Teva Greater China.
  • Chorea, one of the most striking physical manifestations of Huntington’s disease, is a neurological disorder that causes involuntary, random muscle movements.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd., founded in 1978, is a leading CNS company in China.

Kinetic Global Unveils Revolutionary AI-Powered Incident Manager For Business Continuity And Corporate Security Teams at DRI International Conference

Retrieved on: 
Monday, February 26, 2024
Documentation, Extremities, CCTV, Development, Weather, Conference, Risk management

CHICAGO, Feb. 26, 2024 /PRNewswire-PRWeb/ -- Crafted with Precision for High-Stakes Decision-Making

Key Points: 
  • Clandestine Development, Inc., DBA-Kinetic Global—the global leader in critical event management and emergency mass notification applications—today announced Incident Manager.
  • In an era where operational disruptions are not an 'if,' but a 'when,' Kinetic Global introduces a groundbreaking solution to the enterprise challenge of real-world events impacting critical assets – the Incident Manager.
  • This sophisticated module, an extension of Kinetic Global's Enterprise Critical Event Management Platform, debuts at the DRI International Conference, reflecting a full suite of capabilities designed specifically for corporate security and business continuity teams.
  • Kinetic Global's Incident Manager is crafted with direct insights from industry leaders, ensuring a coupled approach of advanced technology with practical workflow intuitiveness.

Herbal medicinal product: Cimicifugae rhizomaArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Woman, Committee, Ethanol, Liver, Skin, Nausea, Vomiting, Date, Mouth, Urinary system, Safety, Somatic symptom disorder, Diarrhea, Itch, Rash, Patient, Medicine, Urine, Indigestion, Extremities, Herbal medicine, Fatigue, Face, Perspiration

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of black cohosh.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing black cohosh.
  • Black cohosh preparations may also be found in combination with other herbal substances in some herbal medicines.
  • - Therapeutic area
    - Urinary tract and genital disorders
    - Status
    - C: ongoing call for scientific data
    - Date added to the inventory
    - Date added to priority list
    - Outcome of European assessment
    - European Union herbal monograph

Efemoral Medical Granted Breakthrough Device Designation

Retrieved on: 
Wednesday, February 14, 2024
Survivor, Tortuosity, CMO, PAOD, LOS, Vascular disease, FDA, Quality of life, De novo, Foot, Leg, Entrepreneurship, CLTI, Health, Prognosis, Patient, Artery, Extremities, Diagnosis, Moyamoya disease, Pharmaceutical industry

LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that the United States Food & Drug Administration (FDA) has granted its novel Efemoral Vascular Scaffold System (EVSS) Breakthrough Device status for the treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with Chronic Limb Threatening Ischemia (CLTI).

Key Points: 
  • LOS ALTOS, Calif., Feb. 14, 2024 /PRNewswire/ -- Efemoral Medical , developer of advanced interventional bioresorbable therapies, today announced that the United States Food & Drug Administration (FDA) has granted its novel Efemoral Vascular Scaffold System (EVSS) Breakthrough Device status for the treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with Chronic Limb Threatening Ischemia (CLTI).
  • The device designed for above-the-knee (femoropopliteal) intervention is currently being tested in a first-in-human trial, EFEMORAL I, in investigative sites in New Zealand and Australia.
  • Encouraged by the early clinical results, Efemoral Medical is now developing an additional device for treating below-the-knee (infrapopliteal) arteries in patients with CLTI.
  • We are extremely gratified that the FDA has recognized the potential of the EVSS to benefit these patients by granting Breakthrough Device status to our device."

Dr. Chad Stephens Joins Physician Partners of America in Texas

Retrieved on: 
Thursday, February 8, 2024
Radiofrequency ablation, Society, Tendon, Partner, American Academy, Health, Interventional pain management, Partnership, Private practice, Chronic pain, Marketing, Patient, Physical medicine and rehabilitation, Tenotomy, Extremities, Knowledge, Dentistry

FORT WORTH, Texas, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce a partnership with Noble Pain Management and Sports Medicine (Noble Pain and Sports). They are excited to welcome the founder of Noble Pain and Sports, interventional pain management and sports medicine physician, Chad Stephens, DO, to their Fort Worth North practice in Texas. He is now seeing patients at the office, located at 4364 Heritage Trace Pkwy #112B, Fort Worth, TX 76244.

Key Points: 
  • Physician Partners of America acquires Noble Pain Management & Sports Medicine.
  • FORT WORTH, Texas, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce a partnership with Noble Pain Management and Sports Medicine (Noble Pain and Sports).
  • They are excited to welcome the founder of Noble Pain and Sports, interventional pain management and sports medicine physician, Chad Stephens, DO, to their Fort Worth North practice in Texas.
  • Joining a group of well-established pain partners, I hope to help lead how quality Interventional Pain Management is provided in Texas."

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Retrieved on: 
Thursday, February 1, 2024
Traction, Growth, Umbilical cord, Extracellular matrix, Extremities, Regenerative medicine, Chronic pain, Combination, Collagen, Pelvis, CELU, Cytokine, Knee, Environment, Exosome, FDA, Disorder, Osteoarthritis, Device, Food, Decellularization, Dentistry, Protein, Disability, Chemokine, Sale, Tissue, GMP, Burns, Pharmaceutical industry

FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline. As used here, “net sales” refers exclusively to revenue from the sale of advanced biomaterial products and biobanking services, respectively, and does not include any revenue from other sources such as license fees and royalties or revenue earned under research collaboration agreements.

Key Points: 
  • FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.
  • “Our sales of advanced biomaterial products grew dramatically in the fourth quarter of 2023 as our newest Biovance 3L product gained traction.
  • The Company expects in future to update expected full year 2024 net sales of its advanced biomaterial product and biobanking businesses.
  • The Company’s advanced biomaterial product pipeline consists of four commercial-stage products and three development-stage product candidates.